Ardan Equity and GI Partners take co-control of Clinical Ink

Ardan Equity and GI Partners have taken co-control of Clinical Ink, according to a report in the primary source dated October 19, 2026. The Winston-Salem, North Carolina-based company provides electronic clinical outcome assessment and connected device technology to drugmakers and contract research organizations.

The available source material is limited to the headline and an introductory description, and does not disclose the transaction's financial terms, the identity of any prior owners, or the structure of the co-control arrangement. Readers seeking deal value or governance details will need to consult the full original report.

For institutional investors, the transaction reflects continued private equity interest in clinical trial technology infrastructure, where electronic outcome assessment and connected devices are used to collect patient-reported and clinician-reported data in drug development programs.